Compare iShares MSCI Australia ETF (EWA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Tango Therapeutics Inc. — how do they compare? iShares MSCI Australia ETF trades at $28.55 (market cap $1.20B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 3.1× iShares MSCI Australia ETF's market cap, and Tango Therapeutics Inc. is more actively traded (9,619,106 versus 1,742,887). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Australia ETF for 61 Days and Tango Therapeutics Inc. for 0 Days on average.
| EWA | TNGX | |
|---|---|---|
Market Cap | $1.20B | $3.75B |
Volume | 1,742,887 | 9,619,106 |
Sector | Broad Market / Factor | Health |
52-Week High | $30.43 | $32.90 |
52-Week Low | $24.95 | $7.50 |
Typical Hold Time | 61 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA, the iShares MSCI Australia ETF, trades at $28.77, up 0.35% today, but technical indicators signal a bearish trend with moving averages and key oscillators like the 6-day RSI at 75.94 suggesting overbought conditions. The ETF tracks Australian equities, heavily weighted toward commodities and financials, with recent news highlighting institutional selling by Squarepoint Ops LLC amid broader market concerns over inflation and oil price volatility.
The outlook for EWA hinges on commodity demand and global economic trends, offering exposure to Australia's resource-driven economy but facing risks from inflation and geopolitical tensions. Analyst sentiment is mixed, with Seeking Alpha rating it a Buy targeting over 20% upside, while technical weakness and institutional selling pose near-term headwinds.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
